Department of Gynaecology and Obstetrics, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Graduate School, Xuzhou Medical University, Xuzhou, China.
Hum Cell. 2022 May;35(3):896-908. doi: 10.1007/s13577-022-00681-w. Epub 2022 Feb 16.
Ovarian cancer is one of the most lethal gynecologic malignancies worldwide, with the 5-year survival is less than 50%. Although some clinical achievements have been achieved, the overall survival rate has remained unchanged over the past 20 years. Therefore, it is necessary and urgent to develop the potential modifiers and therapeutic approach to improve the overall survival rate in ovarian cancer patients. RBCK1 is an RING protein E3 ubiquitin ligase, which was revealed to involve in the progression of several cancers through its ubiquitination function. In this research, we report that RBCK1 expression is significantly elevated in human ovarian cancer and strongly associated with poor patients' prognosis. RBCK1 deficiency induces cell apoptosis and inhibits cell proliferation and migration in ovarian cancer cells. In terms of molecular mechanism, we report that RBCK1 interacts with PTEN and promotes PTEN degradation in K48-linked ubiquitination. Our study suggests a new and interesting regulatory mechanism that RBCK1 facilitates PTEN degradation, which could be a new potential therapeutic target for ovarian cancer treatment.
卵巢癌是全球致死率最高的妇科恶性肿瘤之一,5 年生存率不足 50%。尽管取得了一些临床成果,但在过去的 20 年中,总体生存率仍未改变。因此,有必要和迫切需要开发潜在的修饰因子和治疗方法,以提高卵巢癌患者的总体生存率。RBCK1 是一种 RING 蛋白 E3 泛素连接酶,其通过泛素化功能被揭示参与了几种癌症的进展。在这项研究中,我们报告 RBCK1 在人卵巢癌中的表达显著上调,并与患者预后不良密切相关。RBCK1 缺失诱导卵巢癌细胞凋亡,并抑制细胞增殖和迁移。在分子机制方面,我们报告 RBCK1 与 PTEN 相互作用,并促进 PTEN 在 K48 连接泛素化中的降解。我们的研究提出了一个新的和有趣的调节机制,即 RBCK1 促进 PTEN 降解,这可能成为卵巢癌治疗的一个新的潜在治疗靶点。